Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 68788-4026

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68788-4026). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Phamaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

An instructional diagram showing a capsule being opened with delayed-release pellets pouring out, likely illustrating the contents and administration related to Duloxetine delayed-release capsules. The image is black and white with simple line art style.*

FDA Label Image

Figure6 (Image 10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at 20 mg, 60 mg, and 120 mg once daily doses, and placebo. The x-axis shows percent improvement in pain (0 to 100%), and the y-axis shows the percentage of patients improved (0 to 100%). Four distinct lines represent each treatment group.*

FDA Label Image

Figure 7 (Image 11)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline. It shows two lines: one for Duloxetine Delayed-Release 60 mg once daily and one for placebo, tracking improvement across increasing pain relief percentages.*

FDA Label Image

Figure8 (Image 12)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It shows data for Duloxetine delayed-release 60 mg/120 mg once daily and placebo groups, with the x-axis representing percent improvement in pain and the y-axis representing percentage of patients improved.*

FDA Label Image

Figure9 (Image 13)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine delayed-release 60 mg once daily and placebo. The x-axis represents percent improvement in pain, and the y-axis shows percentage of patients improved, with data points plotted for both treatments across a range of improvement percentages.*

FDA Label Image

Figure10 (Image 14)

A line graph displaying the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares Duloxetine delayed-release 60/120 mg once daily to placebo, showing higher patient improvement percentages with Duloxetine across pain improvement levels.*

FDA Label Image

1 (Image 16)

FDA Label Image

1 (Image 17)

FDA Label Image

Duloxetine Delayed-release Cap Usp 30mg (Image 19)

The label for Duloxetine Delayed-Release Capsules USP 30 mg by Balkanpharma Dupnitsa AD, generic for Cymbalta. The capsule contains 33.7 mg Duloxetine Hydrochloride equivalent to 30 mg Duloxetine. The label includes storage instructions, caution about federal law, a barcode, and spaces for batch, expiration, and lot numbers. It features bilingual directions in English and Spanish for dosage instructions.*

FDA Label Image

1 (Image 2)

Instructional illustration depicting two hands demonstrating proper capsule administration technique, likely showing how to open or handle the capsule for oral use. No text or branding is visible.*

FDA Label Image

Duloxetine Delayed-release Cap Usp 60mg (Image 20)

Label for Duloxetine Delayed-Release Capsules USP 60mg, generic for Cymbalta, manufactured by Balkanpharma Dupnitsa AD. The label indicates delayed-release pellets form, dosage strength of 60 mg, and includes dosage instructions section in English and Spanish. The capsule is described as gray and white with imprint 2892 2892. Storage and caution information is also present along with barcodes and space for batch and expiration dates.*

FDA Label Image

1 (Image 3)

An illustration diagram showing a cross-section of a delayed-release capsule containing pellets. The image highlights the capsule shell and the internal pellets designed for controlled release of medication.*

FDA Label Image

1 (Image 4)

Chemical structure of Duloxetine, showing the arrangement of atoms and bonds including a naphthalene ring, thiophene ring, and amine hydrochloride group.*

FDA Label Image

Figure1 (Image 5)

A Kaplan-Meier survival curve comparing the proportion of patients with relapse over time in days from randomization. The chart contrasts Duloxetine delayed-release capsules with placebo, showing relapse proportions on the vertical axis and days on the horizontal axis.*

FDA Label Image

Figure2 (Image 6)

A Kaplan-Meier survival curve comparing the proportion of patients with relapse over time between Duloxetine delayed-release capsules and placebo groups. The x-axis shows time from randomization to relapse in days, and the y-axis shows the proportion of patients with relapse. The graph includes a legend distinguishing Duloxetine treatment from placebo.*

FDA Label Image

Figure3 (Image 7)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo, showing their relative effectiveness in pain improvement across different thresholds.*

FDA Label Image

Figure4 (Image 8)

A line graph showing the percentage of patients improved against percent improvement in pain from baseline for Duloxetine 60 mg taken twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo. The graph illustrates comparative patient improvement percentages at various pain improvement thresholds.*

FDA Label Image

Figure5 (Image 9)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg taken twice daily, Duloxetine 60 mg once daily, and placebo. The graph shows three lines representing different treatment groups and their pain improvement distribution across various percent improvement intervals.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.